期刊文献+

95例国产注射用伏立康唑不良反应分析 被引量:7

Analysis of 95 Cases of Adverse Drug Reactions Induced by Domestic Voriconazole for Injection
原文传递
导出
摘要 目的:探讨国产注射用伏立康唑致药品不良反应(ADR)的特点,为临床合理用药提供参考。方法:对某三甲医院2014~2018年发生的国产注射用伏立康唑ADR进行监测,分析ADR的临床表现与累及器官-系统、发生时间、联合用药以及转归等。结果:发生的95例ADR以65岁以上患者为主(占69.47%),男性多于女性,发生在用药7 d内的占84.21%;患者使用伏立康唑的用法用量均符合说明书要求、发生ADR临床表现复杂多样,累及器官-系统以循环系统(31.36%)、呼吸系统(23.67%)、皮肤及其附件损害(13.02%)、神经系统(7.10%)较为多见;有2例ADR考虑为双硫仑样反应;严重ADR 9例;除1例转归不详外,其他患者均转归良好。结论:使用国产注射用伏立康唑期间应密切监测ADR,尤其对老年患者应加强关注,注意联合用药避免双硫仑样反应等的发生,以保障患者的用药安全。 Objective:To investigate the characteristics of adverse drug reactions(ADRs)induced by domestic voriconazole for injection and provide reference for clinical rational drug use.Methods:The ADRs of domestic voriconazole for injection were monitored in a gradeⅢand class A hospital from 2014 to 2018.The clinical manifestations,system-organ damages,occurrence time,drug combination and prognosis of ADRs,etc were analyzed.Results:Totally 95 cases of ADRs occurred mainly in the patients over 65 years old(69.47%)and male patients had more ADRs than female patients.The ADRs often occurred within 7 d after medication,which accounted for 84.21%.Dosage and application of all patients were conformed with drug instruction of voriconazole.The ADRs involved multiple organs and systems,and the clinical manifestations were various.The main damaged systems were circulatory system(31.36%),respiratory system(23.67%),skin and its attachment(13.02%)and nervous system(7.10%).Two cases were determined as disulfiram-like reactions.Nine cases appeared serious adverse reactions.The prognosis was better after the corresponding treatment.Conclusion:The strengthening of ADRs monitoring for domestic voriconazole can ensure the safety of medication,especially in elderly patients,and attention should be paid to the combination of drugs to avoid the occurrence of disulfiram-like reactions.
作者 席兰艳 鲁虹 史群志 毛艳梅 刘芳群 Xi Lanyan;Lu Hong;Shi Qunzhi;Mao Yanmei;Liu Fangqun(Department of Pharmacy,Changsha Central Hospital,Changsha 410004,China)
出处 《中国药师》 CAS 2020年第1期116-119,共4页 China Pharmacist
关键词 伏立康唑 药品不良反应 监测 安全用药 Voriconazole Adverse drug reactions Mornitoring Safe medication
  • 相关文献

参考文献6

二级参考文献55

  • 1肖静,康学军,黄晓.注射用伏立康唑专用溶剂的气相色谱含量测定[J].化学试剂,2005,27(10):616-618. 被引量:4
  • 2卢熠,何文威.医院开展药品不良反应监测的现状及改进建议[J].中国药业,2006,15(12):40-41. 被引量:5
  • 3周新.解读侵袭性肺部真菌感染的诊断标准与治疗原则(草案)[J].中国实用内科杂志,2006,26(11):1752-1753. 被引量:19
  • 4程民.羟丙基β-环糊精对伏立康唑增溶作用的研究[J].安徽医药,2007,11(3):207-208. 被引量:8
  • 5GHANNOUM MA,KUHN DM.Voriconazole-better chances for patients with invasive mycoses[J].Eur J Med Res,2002,7 (5) :242-256.
  • 6PFALLER MA,DIEKEMA DJ,JONES RN,et al. International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 19
  • 7ESPINEL-INGROFF A.In vitro activity of the new triazole voriconazole(UK-109,496)against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens[J].J Clin Microbiol, 1998,36 ( 1 ) :198-202.
  • 8ESPINEL-INGROFF A.In vitro fungicidal activities of voriconazole,itraconazole,and amphotericin B against opportunistic moniliaceous and dematiaceous fungi[J].J Clin MicrobioI,2001,39 (3) :954-958.
  • 9CARRILLO AJ,GUARRO J.In vitro activities of four novel triazoles against Scedosporium spp[J].Antimicrob Agents Chemother, 2001,45 ( 7 ) :2151-2153.
  • 10PURKINS L,WOOD N,GHAHRAMANI P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].Antimicrob Agents Chemother, 2002,46 (8) :2546-2553.

共引文献78

同被引文献76

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部